Table 3.
Cox regression analysis for prediction of OS in 203 patients with intermediate tumor burden
| Variables | Univariable analysis |
Multivariable analysis |
||
|---|---|---|---|---|
| HR (95% Cl) | p value | HR (95% Cl) | p value | |
| Age, 1 year increase | 1.02 (1.01–1.04) | 0.011 | 1.01 (0.99–1.03) | 0.193 |
| Male (vs. female) | 0.85 (0.50–1.45) | 0.557 | 0.98 (0.57–1.67) | 0.938 |
| FIB-4 index, 1 point increase | 1.06 (1.02–1.11) | 0.005 | 0.96 (0.90–1.03) | 0.256 |
| ALBI score, 1 point increase | 2.71 (1.89–3.89) | <0.001 | 2.19 (1.30–3.68) | 0.003 |
| AFP, 1 ng/mL increase | 1.00 (1.00–1.00) | 0.840 | ||
| HBV positive (vs. negative) | 1.10 (0.71–1.71) | 0.678 | ||
| HCV positive (vs. negative) | 1.07 (0.66–1.73) | 0.794 | ||
| Cirrhosis (vs. no) | 1.88 (1.18–3.00) | 0.008 | 1.26 (0.74–2.15) | 0.388 |
| SR versus TACE | 0.29 (0.18–0.46) | <0.001 | 0.45 (0.27–0.75) | 0.002 |
OS, overall survival; HR, hazard ratio; Cl, confidence interval; FIB-4 index, fibrosis-4 index; ALBI score, albumin-bilirubin score; AFP, a-fetoprotein; HBV, hepatitis B virus; HCV, hepatitis C virus; SR, surgical resection; TACE, transarterial chemoembolization.